See every side of every news story
Published loading...Updated

Obesity drug prices are dropping, but getting a steady supply remains a challenge

UNITED STATES AND UNITED KINGDOM, JUL 7 – Drug prices for obesity treatments like Wegovy and Zepbound have declined due to competition and new developments, but supply shortages and uneven insurance coverage keep access limited.

  • On July 1, CVS Health's PBM dropped Zepbound from its formulary as prices for Wegovy and Zepbound fell to around $500 monthly, but access remains inconsistent.
  • Rising competition from pill versions and complex manufacturing challenges explain the recent price drops and ongoing supply constraints for GLP-1 injectable obesity drugs.
  • Despite falling prices, partial insurance coverage leads to hundreds of dollars in monthly costs for patients and some large employers dropping drug coverage, says Dr. Beverly Tchang.
  • Upcoming pill versions from Novo Nordisk and Eli Lilly may arrive within a year, further lowering injectable drug prices and shifting market dynamics, experts say.
Insights by Ground AI
Does this summary seem wrong?

71 Articles

All
Left
14
Center
39
Right
2
Right

Obesity Drug Prices Drop, Supply Still a Challenge

·Washington, United States
Read Full Article
Spectrum Local NewsSpectrum Local News
+3 Reposted by 3 other sources
Center

Wegovy, Zepbound prices fall but access still not guaranteed

Reduced monthly costs for uninsured patients still amount to around $500, but that can put the drugs out of reach for many.

·United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 71% of the sources are Center
71% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Hamilton Spectator broke the news in Hamilton, Canada on Monday, July 7, 2025.
Sources are mostly out of (0)

You have read 1 out of your 5 free daily articles.

Join millions of well-informed readers who use Ground to compare coverage, check their news blindspots, and challenge their worldview.